Helicobacter最新文献

{"title":"Advancing Gastric Cancer Prevention in Korea: Current Strategies and Future Directions","authors":"Jin Young Park,&nbsp;Il Ju Choi","doi":"10.1111/hel.70121","DOIUrl":"10.1111/hel.70121","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Korea has historically borne a high burden of gastric cancer, although substantial epidemiological transitions have occurred over recent decades. Gastric cancer was the most common cancer until 2018, but declined to fifth by 2022. Gastric cancer incidence has decreased steadily, accompanied by marked reductions in mortality and substantial improvements in survival, with 5 year overall survival rate now exceeding 75%. During this period, <i>Helicobacter pylori</i> (<i>H. pylori</i>) seroprevalence has shown a decreasing trend, especially in younger generations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Randomized controlled trials conducted in high-risk groups have demonstrated that <i>H. pylori</i> eradication significantly reduces gastric cancer risk. To further evaluate the role of <i>H. pylori</i> eradication as a primary prevention strategy in the general population, HELPER is currently ongoing in Korea in collaboration with the International Agency for Research on Cancer. For secondary prevention of gastric cancer, the Korean National Cancer Screening Program (KNCSP) was launched in 1999 and provides biennial endoscopic screening for adults aged 40 years or older.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The HELPER study had screened <i>H. pylori</i> status in &gt; 12,000 average-risk Korean participants who had participated in KNCSP up to 2019. Individuals with <i>H. pylori</i> infection were randomized to receive either bismuth quadruple therapy or placebo. The participants have been followed up through the KNCSP, and an interim analysis is planned after a 6 year follow-up period. Secondary prevention through the KNCSP has achieved high participation rates and is strongly associated with reduced gastric cancer mortality, stage migration to early disease, and increased use of endoscopic treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The current uniform screening strategy does not incorporate individual risk stratification and is costly. Future integration of <i>H. pylori</i> eradication and objective assessment of gastric atrophy into risk-adapted screening and surveillance strategies may optimize effectiveness, reduce healthcare costs, and further decrease the burden of gastric cancer in Korea.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Journey Towards Piloting Helicobacter pylori Screen-and-Treat to Address Health Inequities in Aotearoa New Zealand","authors":"Andrea Teng,&nbsp;James Stanley,&nbsp;Melissa McLeod","doi":"10.1111/hel.70123","DOIUrl":"10.1111/hel.70123","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Māori and Pacific peoples in Aotearoa New Zealand (Aotearoa) face the greatest barriers to healthcare access, poorest health outcomes, and disproportionate levels of deprivation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This paper outlines the (1) epidemiology of <i>H. pylori</i> and its sequelae, (2) inequities in the current <i>H. pylori</i> approach, (3) research into screen-and-treat, and (4) our recommendations going forward.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There are stark ethnic differences in prevalence of <i>H. pylori</i> infection and its sequelae in Aotearoa—with higher <i>H. pylori</i> infection prevalence and gastric cancer incidence and higher numbers of hospitalisations for peptic ulcer in Māori, Pacific, and Asian ethnicities than in European. The opportunistic approach taken to <i>H. pylori</i> testing has created inequities. Māori and Pacific are less likely to be tested for <i>H. pylori</i> than European, despite the higher prevalence of infection in these populations. In Aotearoa, a targeted screen-and-treat approach has been shown to be more cost-effective than a population–wide strategy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is an urgent need to introduce a screen-and-treat pilot in Aotearoa, which should be led by Māori. Piloting of screen-and-treat is useful for evaluating invitation, testing and treatment strategies. Further <i>cost</i>–effectiveness modeling could support the evaluation of more specific targeting, test choice, and treatment choice where input data allow.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13047468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147607998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Saccharomyces boulardii CNCM I-745 as Adjunct Therapy for Helicobacter pylori Eradication: Data From the European Registry on H. pylori Management (Hp-EuReg)","authors":"Olga P. Nyssen,&nbsp;Laimas Jonaitis,&nbsp;Ángeles Pérez-Aísa,&nbsp;Bojan Tepes,&nbsp;Umud Mahmudov,&nbsp;Irina Voynovan,&nbsp;Samuel J. Martínez-Domínguez,&nbsp;Luis Bujanda,&nbsp;Alfredo J. Lucendo,&nbsp;Ludmila Vologzanina,&nbsp;Ana Garre,&nbsp;Frode Lerang,&nbsp;Sayar R. Abdulkhakov,&nbsp;Matteo Pavoni,&nbsp;Maja Denkovski,&nbsp;Emin Mammadov,&nbsp;Mārcis Leja,&nbsp;Javier Tejedor-Tejada,&nbsp;Jose M. Huguet,&nbsp;Galyna Fadieienko,&nbsp;Ilchishina Tatiana,&nbsp;Manuel Pabón-Carrasco,&nbsp;Aiman S. Sarsenbaeva,&nbsp;Oleg Zaytsev,&nbsp;Gülüstan Babayeva,&nbsp;Jesús Barrio,&nbsp;Miguel Areia,&nbsp;Monica Perona,&nbsp;Óscar Núñez,&nbsp;Antonietta G. Gravina,&nbsp;Sergey Alekseenko,&nbsp;Blas José Gómez Rodríguez,&nbsp;Quliyev Fərid Vidadi Oğlu,&nbsp;Inmaculada Ortiz-Polo,&nbsp;Antonio Moreno Loro,&nbsp;György Miklós Buzás,&nbsp;Boris D. Starostin,&nbsp;Juozas Kupcinskas,&nbsp;Dmitry S. Bordin,&nbsp;Antonio Gasbarrini,&nbsp;Oleksiy Gridnyev,&nbsp;Ricardo Marcos-Pinto,&nbsp;Manuel Jiménez-Moreno,&nbsp;Mónica Sánchez Alonso,&nbsp;Virginia Flores,&nbsp;Irene Arteagoitia,&nbsp;Anna Cano-Català,&nbsp;Pablo Parra,&nbsp;Leticia Moreira,&nbsp;Javier P. Gisbert,&nbsp;the Hp-EuReg investigators","doi":"10.1111/hel.70119","DOIUrl":"10.1111/hel.70119","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Saccharomyces boulardii</i> CNCM I-745 (Sb) is one of the most widely used probiotics in clinical practice. The aim of this study was to assess the impact of adding Sb to <i>Helicobacter pylori</i> eradication therapy on treatment outcomes (effectiveness and safety) in routine European gastroenterology clinical practice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Treatment-naive cases from the European registry on <i>H. pylori</i> management (Hp-EuReg) collected from 2013 to 2023 at AEG-REDCap were analyzed. Effectiveness was assessed by modified intention-to-treat, by treatment and geographic regions. Multivariate analysis identified factors independently associated with eradication success and adverse event incidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 69,922 cases, probiotics were used in 16,528 (24%) treatments, of which 4404 (27%) included Sb. Sb use was significantly associated with an increase in effectiveness (OR = 2.32; 95% confidence interval, 1.38–4.03; <i>p</i> &lt; 0.01) only when prescribed with concomitant therapy encompassing a proton pump inhibitor plus clarithromycin-amoxicillin-metronidazole. In addition, a significant reduction in the overall incidence of at least one adverse event was observed in the Sb group (OR = 0.803; 0.66–0.97; <i>p</i> &lt; 0.05). Specifically, diarrhea, nausea, dyspepsia, abdominal pain, asthenia, anorexia, heartburn, and dysgeusia occurred significantly less frequently with Sb. Treatment compliance was high in both groups (with and without Sb).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In Europe, the addition of Sb to first-line regimens in clinical practice was associated with higher effectiveness when combined with concomitant therapy with clarithromycin-amoxicillin-metronidazole and with fewer overall adverse events, supporting its role as a beneficial adjunct in <i>H. pylori</i> eradication therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Registration Number</h3>\u0000 \u0000 <p>ClinicalTrials.gov identifier: NCT02328131</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13043801/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter pylori Eradication Primary Care First-Line Prescriptions: Data From 200,000 Patients in a Real-World Cohort","authors":"Encarnación Fernández-Antón,&nbsp;Olga P. Nyssen,&nbsp;Gabriela Alonso-Martínez,&nbsp;Pablo Parra,&nbsp;Miguel Gil,&nbsp;Javier P. Gisbert,&nbsp;Francisco J. de Abajo","doi":"10.1111/hel.70122","DOIUrl":"10.1111/hel.70122","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Helicobacter pylori</i> is a common infection primarily managed in primary care. Assessing real-world practices and guideline adherence is crucial for treatment optimisation. The study aims to assess current <i>H. pylori</i> management strategies using data from BIFAP, a Spanish primary care database.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Cohort study including patients aged ≥ 18 with recorded <i>H. pylori</i> infection (2003–2023) and corresponding treatment prescriptions. Infection cases were identified using ICD-9/10 and SNOMED-CT codes. Treatment patterns were based on Spanish and European guidelines. First-line treatment prescriptions were compared between primary (BIFAP) and specialized (European Registry, Hp-EuReg) care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 211,972 <i>H. pylori-</i>infected subjects were identified. Over the study period (20 years), the predominant first-line treatments were: bismuth quadruple therapy including a proton-pump inhibitor (PPI) plus a single capsule containing bismuth-tetracycline-metronidazole (36%); PPI + clarithromycin-amoxicillin (30%); and PPI + clarithromycin-amoxicillin-metronidazole (26%). Single-capsule bismuth quadruple therapy was the most common in patients aged 18–64 and those with obesity, chronic kidney disease, or smokers, while PPI + clarithromycin-amoxicillin was more common in those aged ≥ 65 or with peptic ulcers. Since 2013, PPI + clarithromycin-amoxicillin use by general practitioners and gastroenterologists decreased, though it remained above 10% in primary care at study end. PPI + clarithromycin-amoxicillin-metronidazole increased since 2015, with higher use in specialized care (40%) vs. primary care (30%). In 2023, single-capsule bismuth quadruple therapy was the most prescribed regimen in both settings, accounting for ~60% of prescriptions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Primary care <i>H. pylori</i> treatments are varied, with single-capsule bismuth quadruple therapy most prescribed. Guidelines are followed, but adoption is slower in primary than in specialized care.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13044324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vonoprazan Versus Tegoprazan–Amoxicillin Dual Therapy for Treatment-Naïve Patients With Helicobacter pylori Infection: A Prospective, Multicenter, Open-Label, Randomized Controlled Study","authors":"Ya-Ni Zhou,&nbsp;Ji-Chun Song,&nbsp;Qing-Hua Wang,&nbsp;Huang Feng,&nbsp;Ya Lin,&nbsp;De-Min Li,&nbsp;Ge Wang,&nbsp;Xiao-Wei Huang,&nbsp;Jing-Mei Liu,&nbsp;Yan Shen,&nbsp;Xiang Zhou,&nbsp;Hui-Ting Xue,&nbsp;Yan Liu,&nbsp;Pei-Yuan Li","doi":"10.1111/hel.70124","DOIUrl":"10.1111/hel.70124","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;High-dose dual therapy (HDDT) has been shown to achieve eradication rates non-inferior to the bismuth quadruple therapy (BQT) in treatment-naïve patients of &lt;i&gt;Helicobacter pylori (H. pylori)&lt;/i&gt; infection, with advantages including greater convenience and fewer adverse events. However, the efficacy of different potassium-competitive acid blockers (P-CABs) in HDDT regimens remains incompletely defined due to variations in their pharmacokinetic properties. Therefore, this study aims to evaluate the eradication rates, incidence of adverse events, and compliance of the dual regimens of vonoprazan/tegoprazan combined with amoxicillin in patients with treatment-naïve &lt;i&gt;H. pylori&lt;/i&gt; infection.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This prospective, multicenter, open-label, randomized controlled clinical trial enrolled newly diagnosed patients with H. pylori infection from six centers in China. All subjects were randomly assigned to the VA group (vonoprazan 20 mg bid+amoxicillin 1 g tid, 14 days) or the TA group (tegoprazan 50 mg bid+amoxicillin 1 g tid, 14 days). The basic information and clinical data of the patients were collected via electronic questionnaires, WeChat, or telephone follow-ups. H. pylori eradication was assessed 4 weeks post-treatment using the urea breath test (UBT). The adverse events and compliance were meticulously recorded throughout the treatment period.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Result&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Between June 2024 and May 2025, 710 patients were randomly assigned, and 653 subjects were included. In the intention-to-treat (ITT) analysis, the eradication rates were 89.3% in the VA group and 76.1% in the TA group, respectively (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). The modified intention-to-treat (mITT) analysis showed rates of 94.6% and 80.8%, respectively (&lt;i&gt;p&lt;/i&gt; &lt; 0.001), and the per-protocol (PP) analysis yielded 95.1% and 81.0%, respectively (&lt;i&gt;p&lt;/i&gt; &lt; 0.001). Although the overall incidence of adverse event rates was comparable between groups (17.2% vs. 13.8%, &lt;i&gt;p&lt;/i&gt; = 0.254), gastrointestinal adverse events were less frequent with TA therapy (9.3% vs. 14.4%, &lt;i&gt;p&lt;/i&gt; = 0.048). Compliance was excellent and comparable in both groups (94.6% vs. 94.1%, respectively, &lt;i&gt;p&lt;/i&gt; = 0.871). None of the factors analyzed significantly influenced eradication rates.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Vonoprazan/amoxicillin dual therapy achieved satisfactory &lt;i&gt;H. pylori&lt;/i&gt; eradication rates with a favorable safety profile in treatment-naïve patients. Tegoprazan/amoxicillin dual therapy was associated with fewer gastrointestinal adverse event incidences, while opti","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter 30 Years On: A Message From the Editor, Emeritus","authors":"David Y. Graham","doi":"10.1111/hel.70118","DOIUrl":"10.1111/hel.70118","url":null,"abstract":"","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association of a Positive Fecal Immunochemical Test With the Risk of Gastroesophageal Cancer: An Age-Sex-H. Pylori Exposure Matched Cohort Study and Cost-Effectiveness Analysis","authors":"Zohar Levi,&nbsp;Naim Abu-Freha,&nbsp;Doron Boltin,&nbsp;Maya Aharoni Golan,&nbsp;Tom Konikoff,&nbsp;Orly Sneh Arbib,&nbsp;Rachel Gingold Belfer,&nbsp;Sapir Eizenstein,&nbsp;Alex Vilkin,&nbsp;Shiri Kusnir,&nbsp;Adi Turgeman,&nbsp;Tanya Babich,&nbsp;Moshe Leshno,&nbsp;Anath A. Flugelman,&nbsp;Hadar Edelman-Klapper,&nbsp;Elizabeth Half-Onn","doi":"10.1111/hel.70120","DOIUrl":"10.1111/hel.70120","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>We evaluated the association between Fecal Immunochemical Test (FIT) results and the risk of gastroesophageal cancer (GEC) in a matched cohort, as well as the cost-effectiveness of a one-time esophagogastroduodenoscopy (EGD) for individuals who tested FIT-positive.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We formed a cohort of individuals aged 50–75 years who underwent FIT testing at Clalit Health in Israel from 2016 to 2019. For each person with a positive FIT result, we matched three individuals with negative results by age, gender, and <i>H. pylori</i> exposure. We used adjusted hazard ratios (adjHRs) to assess the association between a positive FIT result and the risk of GEC within 36 months. We calculated the incremental cost-effectiveness ratio (ICER) for a one-time EGD costing USD 350 in individuals who tested positive for FIT, and considered it cost-effective if below USD 50,000.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 150,391 individuals (47.6% female, median age 62.4 years). During follow-up, 202 cases of GEC were recorded: 0.17% in FIT-positive individuals (64/37,709) and 0.12% in FIT-negative individuals (138/112,682), adjHR 1.39 (95% CI 1.03–1.87). GEC was also associated with <i>H. pylori</i> exposure (adjHR 1.43, 95% CI 1.08–1.90) and immigration from high-risk countries. A one-time EGD demonstrated favorable cost-effectiveness across various scenarios, with an ICER of USD 25,535/QALY.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This matched-cohort study suggests that individuals with a positive FIT may have an increased risk of GEC, comparable to that of established high-risk populations. Adding a one-time EGD to colonoscopy for FIT-positive individuals may be a cost-effective approach for healthcare systems that can accommodate such interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter pylori, Inflammation, and Long-Term Outcome in Patients With Acute Myocardial Infarction: A Prospective Cohort Study","authors":"Martin O. Sundqvist,&nbsp;Jonatan Wärme,&nbsp;Marcus Hjort,&nbsp;Per Tornvall,&nbsp;Tomas Jernberg,&nbsp;Bertil Lindahl,&nbsp;Alexandru Schiopu,&nbsp;Tomasz Baron,&nbsp;Stefan H. Jacobson,&nbsp;Thomas Kahan,&nbsp;David Erlinge,&nbsp;Jonas Spaak,&nbsp;Robin Hofmann","doi":"10.1111/hel.70116","DOIUrl":"10.1111/hel.70116","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Helicobacter pylori</i> (Hp) and its virulence factor Cytotoxin-associated gene A (CagA) have been linked to myocardial infarction (MI), but the mechanisms are unknown. This study aims to test if Hp infection and CagA are associated with pre-specified inflammatory and vascular biomarkers in patients with MI and to explore whether a broader biomarker panel can predict infection. Furthermore, it aims to investigate the association of Hp infection and biomarkers with major adverse cardiovascular events (MACE) and mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Hp, CagA serology, and 175 cardiovascular biomarkers were analyzed in 1061 patients with MI admitted between 2008 and 2014. Associations between Hp and seven pre-selected biomarkers were evaluated. Exploratory analyses included all biomarkers using machine-learning models to predict Hp-status. Hp-status and the top predictors were analyzed for associations with outcomes using Cox regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Median age was 65 years; 78% were male. Hp and CagA seroprevalence were 45% and 19%, respectively. Patients with Hp had elevated CRP (<i>β</i> = 0.26, 95% CI 0.01–0.51). Predictive performance of Hp-status was moderate (AUC 0.63–0.68). Exploratory analysis identified higher levels of C-C motif chemokine ligand 20 (CCL20) and immunoglobulin heavy constant gamma-3 (IGHG3), and lower levels of TNF-related apoptosis-inducing ligand (TRAIL) in patients with Hp-positivity. Elevated CCL20 and reduced TRAIL, but not Hp, were associated with MACE and all-cause mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Hp may contribute to an inflammatory response in patients with MI, indicated by higher CRP and inflammatory/immune-modulatory biomarkers emerging as its top predictors. Although Hp was not associated with adverse outcomes after MI, its predictive inflammatory biomarkers were associated with MACE and mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>The study was not registered as a clinical trial, as it was an observational study</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12989639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147463401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes of Helicobacter pylori Infection Status and Risk of Precancerous Lesions: A Prospective Cohort Study in Chinese Population","authors":"Xufei Xing,&nbsp;Renjia Zhao,&nbsp;Zixuan Cui,&nbsp;Qiaoyi Xu,&nbsp;Ziyu Yuan,&nbsp;Kelin Xu,&nbsp;Tiejun Zhang,&nbsp;Zhenqiu Liu,&nbsp;Yanfeng Jiang,&nbsp;Ming Lu,&nbsp;Weimin Ye,&nbsp;Chen Suo,&nbsp;Xingdong Chen","doi":"10.1111/hel.70114","DOIUrl":"10.1111/hel.70114","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the associations of both baseline serological profiles and serological transitions of <i>Helicobacter pylori</i> infection patterns with the risk of precancerous gastric lesions (PGLs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>We analyzed data from 6208 participants in the FuSion cohort who underwent gastroscopy examination, with available <i>H. pylori</i> antibody and pepsinogen measurements at both baseline and follow-up. <i>H. pylori</i> status defined by IgG antibodies (Ab) and pepsinogens (PG), classified participants into four ABC groups. Multivariable logistic regression evaluated associations with PGLs across baseline and transition statuses. Trend tests were performed across the ABC groups and infection transition categories.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A significant increasing trend in the PGLs prevalence and severity was observed across the ABC groups (<i>p</i> for trend &lt; 0.05). Analysis of infection transitions revealed graded risk increases for PGLs from consistently negative to remained positive groups. Interestingly, even participants who seroreverted remained at significantly elevated risks of atrophic gastritis (adjusted odds ratio [aOR] = 2.01, 95% CI: 1.67–2.43) and intestinal metaplasia (aOR = 1.72, 95% CI: 1.14–2.51) compared to the persistently negative participants. The sensitivity analyses excluding baseline PG-positive subjects yielded similar results.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Long-term exposure to <i>H. pylori</i> is associated with an increased risk of PGLs, and this risk may remain elevated even after seroreversion.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147364877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Benefits-Harms of H. pylori Screen-and-Treat Programs Tailored to the Regional Settings","authors":"Duco T. Mülder,&nbsp;Yi-Chia Lee,&nbsp;Mario Dinis-Ribeiro,&nbsp;Melissa McLeod,&nbsp;Jin Young Park,&nbsp;Iris Lansdorp-Vogelaar","doi":"10.1111/hel.70111","DOIUrl":"10.1111/hel.70111","url":null,"abstract":"<p>This article outlines how decision modeling can be used to optimize the cost-effectiveness of <i>H. pylori</i> screen-and-treat programs. Decision models enable the translation of data from pilot studies into locally tailored strategies by adapting test modalities, treatment options, and the need to retest specific to the local setting. We summarize existing evidence from modeling studies, which consistently demonstrate that <i>H. pylori</i> screen-and-treat is cost-effective across diverse populations. In addition, we discuss how decision modeling can support resource allocation, promote health equity, and guide implementation planning. Integrating <i>H. pylori</i> screen-and-treat into established preventive programs, such as colorectal cancer screening, may further increase efficiency and feasibility. The article concludes with a proposed research agenda to advance efficient <i>H. pylori</i> screen-and-treat programs across the globe.</p>","PeriodicalId":13223,"journal":{"name":"Helicobacter","volume":"31 2","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12960071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}